Mircea Badara, MD
Pulmonary Disease · New Britain, CTNPI 1801877865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 671 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,531, more than ten times the $175 reported in 2019.
Across 671 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Mallinckrodt Hospital Products Inc.$900
- Regeneron Healthcare Solutions, Inc.$686
- Sanofi$631
- Boehringer Ingelheim$613
- plus $5K from 38 others
Across 102 payments — averaging $9700.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$744K
- AstraZeneca$225K
- CSL Behring$21K
What the payments were for
- Food & beverage$13,09196%
- Education$5154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOT DX$135
How this compares
$13,606 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 390 | $302,889 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 165 | $119,153 |
| XolairOmalizumab | 26 | $90,279 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 149 | $86,223 |
| Fasenra PenBenralizumab | 12 | $74,200 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $57,562 |
| NucalaMepolizumab | 12 | $51,526 |
| SymbicortBudesonide/Formoterol Fumarate | 154 | $49,434 |
| Breo ElliptaFluticasone/Vilanterol | 107 | $48,264 |
| Spiriva RespimatTiotropium Bromide | 51 | $46,236 |
| EliquisApixaban | 53 | $31,748 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 135 | $25,291 |
| SunosiSolriamfetol Hcl | 13 | $16,142 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $14,089 |
| DuleraMometasone/Formoterol | 25 | $13,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $2,715 | $483,053657 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $2,938 | $172,916334 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $613 | $140,568213 claims |
| PfizerEliquis | $109 | $31,74853 claims |
| Axsome Therapeutics, Inc.Sunosi | $261 | $16,14213 claims |
| MerckDulera | $51 | $13,72225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Britain
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.